Major nutritional issues in the management of Parkinson's disease†
Michela Barichella MD
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy
Search for more papers by this authorCorresponding Author
Emanuele Cereda MD
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy
International Center for the Assessment of Nutritional Status (ICANS), University of Milan, Milan, Italy
International Center for the Assessment of Nutritional Status (ICANS), University of Milan, via Botticelli 21, 20133 Milan, ItalySearch for more papers by this authorGianni Pezzoli MD
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy
Search for more papers by this authorMichela Barichella MD
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy
Search for more papers by this authorCorresponding Author
Emanuele Cereda MD
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy
International Center for the Assessment of Nutritional Status (ICANS), University of Milan, Milan, Italy
International Center for the Assessment of Nutritional Status (ICANS), University of Milan, via Botticelli 21, 20133 Milan, ItalySearch for more papers by this authorGianni Pezzoli MD
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy
Search for more papers by this authorPotential conflict of interest: The authors also certify that there are no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed herein.
This article is part of the journal's online CME program. The CME activity including form, can be found online at http://www.movementdisorders.org/education/journalcme/
Abstract
As with other neurodegenerative diseases, neurologic and nutritional elements may interact affecting each other in Parkinson's disease (PD). However, the long-term effects of such interactions on prognosis and outcome have not been given much attention and are poorly addressed by current research. Factors contributing to the clinical conditions of patients with PD are not only the basic features of PD, progression of disease, and the therapeutic approach but also fiber and nutrient intakes (in terms of both energy and protein content), fluid and micronutrient balance, and pharmaconutrient interactions (protein and levodopa). During the course of PD nutritional requirements frequently change. Accordingly, both body weight gain and loss may occur and, despite controversy, it seems that both changes in energy expenditure and food intake contribute. Nonmotor symptoms play a significant role and dysphagia may be responsible for the impairment of nutritional status and fluid balance. Constipation, gastroparesis, and gastro-oesophageal reflux significantly affect quality of life. Finally, any micronutrient deficiencies should be taken into account. Nutritional assessments should be performed routinely. Optimization of pharmacologic treatment for both motor and nonmotor symptoms is essential, but nutritional interventions and counseling could and should also be planned with regard to nutritional balance designed to prevent weight loss or gain; optimization of levodopa pharmacokinetics and avoidance of interaction with proteins; improvement in gastrointestinal dysfunction (e.g., dysphagia and constipation); prevention and treatment of nutritional deficiencies (micronutrients or vitamins). A balanced Mediterranean-like dietary regimen should be recommended before the introduction of levodopa; afterward, patients with advanced disease may benefit considerably from protein redistribution and low-protein regimens. © 2009 Movement Disorder Society
REFERENCES
- 1 Luchsinger JA,Gustafson DR. Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care 2009; 12: 15–21.
- 2 Hu G,Jousilahti P,Nissinen A,Antikainen R,Kivipelto M,Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 2006; 67: 1955–1099.
- 3 Abbott RD,Ross GW,White LR, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002; 59: 1051–1057.
- 4 Cereda E,Sansone V,Meola G,Malavazos AE. Increased visceral adipose tissue rather than BMI as a risk factor for dementia. Age Ageing 2007; 36: 488–491.
- 5 Chen H,Zhang SM,Schwarzschild MA,Hernán MA,Willett WC,Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol 2004; 159: 547–555.
- 6 Kashihara K. Weight loss in Parkinson's disease. J Neurol 2006; 253( Suppl 7): VII38–VII41.
- 7 Barichella M,Marczewska A,Vairo A,Canesi M,Pezzoli G. Is underweightness still a major problem in Parkinson's disease patients? Eur J Clin Nutr 2003; 57: 543–547.
- 8 Barichella M,Villa MC,Massarotto A, et al. Mini Nutritional Assessment in patients with Parkinson's disease: correlation between worsening of the malnutrition and increasing number of disease-years. Nutr Neurosci 2008; 11: 128–134.
- 9 White H,Pieper C,Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998; 46: 1223–1227.
- 10 REAL.FR Group. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. J Nutr Health Aging 2005; 9: 75–80.
- 11 Ousset PJ,Nourhashemi F,Reynish E,Vellas B. Nutritional status is associated with disease progression in very mild Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 66–71.
- 12 Uc EY,Struck LK,Rodnitzky RL,Zimmerman B,Dobson J,Evans WJ. Predictors of weight loss in Parkinson's disease. Mov Disord 2006; 21: 930–936.
- 13 Verbaan D,Marinus J,Visser M,van Rooden SM,Stiggelbout AM,van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007; 69: 333–341.
- 14 Fox SH,Lang AE. Levodopa-related motor complications—Phenomenology. Mov Disord 2008; 23( Suppl 3): S509–S514.
- 15 Cereda E,Valzolgher L,Pedrolli C. Mini nutritional assessment is a good predictor of functional status in institutionalised elderly at risk of malnutrition. Clin Nutr 2008; 27: 700–705.
- 16 Schapira AHV. Parkinson's disease. BMJ 1999; 318: 311–314.
- 17 Quinn N. Parkinsonism—recognition and differential diagnosis. BMJ 1995; 310: 447–452.
- 18 Lorefält B,Ganowiak W,Wissing U,Granérus AK,Unosson M. Food habits and intake of nutrients in elderly patients with Parkinson's disease. Gerontology 2006; 52: 160–168.
- 19 Markus HS,Cox M,Tomkins AM. Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity. Clin Sci (Lond) 1992; 83: 199–204.
- 20 Markus HS,Tomkins AM,Stern GM. Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 1993; 5: 117–125.
- 21 Kumru H,Santamaria J,Valldeoriola F,Marti MJ,Tolosa E. Increase in body weight after pramipexole treatment in Parkinson's disease. Mov Disord 2006; 21: 1972–1974.
- 22 Barichella M,Marczewska AM,Mariani C,Landi A,Vairo A,Pezzoli G. Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Mov Disord 2003; 18: 1337–1340.
- 23 Macia F,Perlemoine C,Coman I, et al. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 2004; 19: 206–212.
- 24 Calabresi P,Di Filippo M,Ghiglieri V,Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008; 23( Suppl 3): S570–S579.
- 25 Pare S,Barr SI,Ross SE. Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients. Am J Clin Nutr 1992; 55: 701–707.
- 26 Barichella M,Marczewska A,De Notaris R, et al. Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease. Mov Disord 2006; 21: 1682–1687.
- 27 Logroscino G,Sesso HD,Paffenbarger RSJr,Lee IM. Body mass index and risk of Parkinson's disease: a prospective cohort study. Am J Epidemiol 2007; 166: 1186–1190.
- 28 Chen H,O'Reilly EJ,Schwarzschild MA,Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008; 167: 90–95.
- 29 Hu G,Jousilahti P,Bidel S,Antikainen R,Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007; 30: 842–847.
- 30 Simon KC,Chen H,Schwarzschild M,Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688–1695.
- 31 Hu G,Antikainen R,Jousilahti P,Kivipelto M,Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008; 70: 1972–1979.
- 32 Driver JA,Smith A,Buring JE,Gaziano JM,Kurth T,Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008; 31: 2003–2005.
- 33 Huang X,Abbott RD,Petrovitch H,Mailman RB,Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008; 23: 1013–1018.
- 34 de Lau LM,Koudstaal PJ,Hofman A,Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006; 164: 998–1002.
- 35 Abbott RA,Cox M,Markus H,Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992; 46: 879–884.
- 36 Lorefält B,Ganowiak W,Pålhagen S,Toss G,Unosson M,Granérus AK. Factors of importance for weight loss in elderly patients with Parkinson's disease. Acta Neurol Scand 2004; 110: 180–187.
- 37 Chen H,Zhang SM,Hernán MA,Willett WC,Ascherio A. Weight loss in Parkinson's disease. Ann Neurol 2003; 53: 676–679.
- 38 Levi S,Cox M,Lugon M,Hodkinson M,Tomkins A. Increased energy expenditure in Parkinson's disease. BMJ 1990; 301: 1256–1257.
- 39 Delikanaki-Skaribas E,Trail M,Wong WW,Lai EC. Daily energy expenditure, physical activity, and weight loss in Parkinson's disease patients. Mov Disord 2009; 24: 667–671.
- 40 Toth MJ,Fishman PS,Poehlman ET. Free-living daily energy expenditure in patients with Parkinson's disease. Neurology 1997; 48: 88–91.
- 41 Ross GW,Petrovitch H,Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167–173.
- 42 Montaurier C,Morio B,Bannier S, et al. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain 2007; 130: 1808–1018.
- 43 Moro E,Scerrati M,Romito LM,Roselli R,Tonali P,Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999; 53: 85–90.
- 44 Nirenberg MJ,Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21: 524–529.
- 45 Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601–607.
- 46 Bachmann CG,Trenkwalder C. Body weight in patients with Parkinson's disease. Mov Disord 2006; 21: 1824–1830.
- 47 Sirtori CR,Bolme P,Azarnoff DL. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 1972; 287: 729–733.
- 48 Davies KN,King D,Davies H. A study of the nutritional status of elderly patients with Parkinson's disease. Age Ageing 1994; 23: 142–145.
- 49 Lipman IJ, Boykin ME, Flora RE. Glucose intalerance in Parkinson's disease. J Chronic Dis 1974; 27: 573–579.
- 50 Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993; 69: 125–130.
- 51 Norman K,Pichard C,Lochs H,Pirlich M. Prognostic impact of disease-related malnutrition. Clin Nutr 2008; 27: 5–15.
- 52 Sato Y,Kaji M,Tsuru T,Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001; 182: 89–93.
- 53 Evatt ML,Delong MR,Khazai N,Rosen A,Triche S,Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008; 65: 1348–1352.
- 54 Nakayama Y,Washio M,Mori M. Oral health conditions in patients with Parkinson's disease. J Epidemiol 2004; 14: 143–150.
- 55 Cersosimo MG,Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008; 23: 1065–1075.
- 56 Lorefält B,Granérus AK,Unosson M. Avoidance of solid food in weight losing older patients with Parkinson's disease. J Clin Nurs 2006; 15: 1404–1412.
- 57 Müller J,Wenning GK,Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 2001; 58: 259–264.
- 58 Natale G,Pasquali L,Ruggieri S,Paparelli A,Fornai F. Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol Motil 2008; 20: 741–749.
- 59 Alfonsi E,Versino M,Merlo IM, et al. Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology 2007; 68: 583–589.
- 60 Nagaya M,Kachi T,Yamada T,Igata A. Videofluorographic study of swallowing in Parkinson's disease. Dysphagia 1998; 13: 95–100.
- 61 Bassotti G,Germani U,Pagliaricci S, et al. Esophageal manometric abnormalities in Parkinson's disease. Dysphagia 1998; 13: 28–31.
- 62 Gross RD,Atwood CWJr,Ross SB,Eichhorn KA,Olszewski JW,Doyle PJ. The coordination of breathing and swallowing in Parkinson's disease. Dysphagia 2008; 23: 136–145.
- 63 Lam K,Lam FK,Lau KK, et al. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Mov Disord 2007; 22: 640–644.
- 64 Manor Y,Giladi N,Cohen A,Fliss DM,Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord 2007; 22: 1917–1921.
- 65 Chou KL,Evatt M,Hinson V,Kompoliti K. Sialorrhea in Parkinson's disease: a review. Mov Disord 2007; 22: 2306–2313.
- 66 Wakabayashi K,Takahashi H,Takeda S,Ohama E,Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988; 76: 217–221.
- 67 Braak H,de Vos RA,Bohl J,Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67–72.
- 68 Byrne KG,Pfeiffer R,Quigley EM. Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J Clin Gastroenterol 1994; 19: 11–16.
- 69 Soykan I,Lin Z,Bennett JP,McCallum RW. Gastric myoelectrical activity in patients with Parkinson's disease: evidence of a primary gastric abnormality. Dig Dis Sci 1999; 44: 927–931.
- 70 Goetze O,Nikodem AB,Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006; 18: 369–375.
- 71 Müller T,Erdmann C,Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006; 29: 61–67.
- 72 Davies KN,King D,Billington D,Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J 1996; 72: 164–167.
- 73 Abbott RD,Petrovitch H,White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456–462.
- 74 Edwards L,Quigley EM,Hofman R,Pfeiffer RF. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov Disord 1993; 8: 83–86.
- 75 Ashraf W,Pfeiffer RF,Park F,Lof J,Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997; 12: 946–951.
- 76 Kupsky WJ,Grimes MM,Sweeting J,Bertsch R,Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37: 1253–1255.
- 77 Ueki A,Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004; 251( Suppl 7): vII18–vII23.
- 78 Singaram C,Ashraf W,Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995; 346: 861–864.
- 79 Cersosimo MG,Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008; 23: 1065–1075.
- 80 Bushmann M,Dobmeyer SM,Leeker L,Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989; 39: 1309–1314.
- 81 Ciucci MR,Barkmeier-Kraemer JM,Sherman SJ. Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson's disease. Mov Disord 2008; 23: 676–683.
- 82 Tison F,Wiart L,Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord 1996; 11: 729–732.
- 83 Born LJ,Harned RH,Rikkers LF,Pfeiffer RF,Quigley EMM. Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Mov Disord 1996; 11: 53–58.
- 84 Restivo DA,Palmeri A,Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med 2002; 346: 1174–1175.
- 85 Zangaglia R,Martignoni E,Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007; 22: 1239–1244.
- 86 Johanson JF. Review of the treatment options for chronic constipation. MedGenMed 2007; 9: 25.
- 87 Hamilton-Miller JM. Probiotics and prebiotics in the elderly. Postgrad Med J 2004; 80: 447–451.
- 88 Sullivan KL,Staffetti JF,Hauser RA,Dunne PB,Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006; 21: 115–116.
- 89 Deane KH,Whurr R,Clarke CE,Playford ED,Ben-Shlomo Y. Non-pharmacological therapies for dysphagia in Parkinson's disease. Cochrane Database Syst Rev 2001; 1: CD002816.
- 90 Logemann JA. Oropharyngeal dysphagia and nutritional management. Curr Opin Clin Nutr Metab Care 2007; 10: 611–614.
- 91 Coggrave M,Wiesel PH,Norton C. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2006; 2: CD002115.
- 92 Vemulapalli R. Diet and lifestyle modifications in the management of gastroesophageal reflux disease. Nutr Clin Pract 2008; 23: 293–298
- 93 Löser C,Aschl G,Hébuterne X, et al. ESPEN guidelines on artificial enteral nutrition--percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005; 24: 848–861.
- 94 Robbins J,Gensler G,Hind J, et al. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial. Ann Intern Med 2008; 148: 509–518.
- 95 Troche MS,Sapienza CM,Rosenbek JC. Effects of bolus consistency on timing and safety of swallow in patients with Parkinson's disease. Dysphagia 2008; 23: 26–32.
- 96 Feinle-Bisset C,Horowitz M. Dietary factors in functional dyspepsia. Neurogastroenterol Motil 2006; 18: 608–618.
- 97 Little TJ,Horowitz M,Feinle-Bisset C. Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. Am J Clin Nutr 2007; 86: 531–541.
- 98 Barclay AW,Petocz P,McMillan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies. Am J Clin Nutr 2008; 87: 627–637.
- 99 Kaltenbach T,Crockett S,Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965–971.
- 100 Goodwin VA,Richards SH,Taylor RS,Taylor AH,Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008; 23: 631–640.
- 101 Olanow CW,Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50(3 Suppl 3 ): S1–S57.
- 102 Marczewska A,De Notaris R,Sieri S,Barichella M,Fusconi E,Pezzoli G. Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. Mov Disord 2006; 21: 1229–1231.
- 103 Berry EM,Growdon JH,Wurtman JJ,Caballero B,Wurtman RJ. A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 1991; 41: 1295–1297.
- 104 Gaenslen A,Gasser T,Berg D. Nutrition and the risk for Parkinson's disease: review of the literature. J Neural Transm 2008; 115: 703–713.
- 105 Postuma RB,Espay AJ,Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006; 66: 1941–1943.
- 106 Zoccolella S,Dell'aquila C,Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord 2009; 24: 1028–1033.
- 107 Rodriguez-Oroz MC,Lage PM,Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. Mov Disord (in press).
- 108 Qualman SJ,Haupt HM,Yang P,Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 1984; 87: 848–856.
- 109 Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006; 63: 210–216.
- 110 Sofi F,Cesari F,Abbate R,Gensini GF,Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008; 337: a1344.